The UKI NETS 2025 Annual Conference will continue to support our NET community to promote collaborations, education and advancement of practice in the field of neuroendocrine neoplasms (NENs).
UKI NETS would like to thank the partners of the 2025 annual meeting:
ESTEVE Pharmaceuticals
ESTEVE Pharmaceuticals is an international pharmaceutical company committed to improving patient care through innovation and solution led thinking.
Following our acquisition of HRA Pharma Rare Diseases in late 2024, we are streamlining our portfolio to deliver innovative programmes that empower healthcare professionals and optimise patient experience. The unified portfolio will address and focus on key therapeutic areas:
- Endocrinology and Oncology: Rare endocrine disorders and complex malignancies.
- Pain Management: Non-opioid therapies.
This unified approach strengthens our mission to address unmet medical needs and deliver impactful patient care worldwide.
Ipsen Ltd – Major Society Partner
Ipsen U.K. and Ireland is a core part of Ipsen’s global biopharmaceutical business and is driven by the belief that patients don’t have time to wait.
Our licensed medicines and R&D are all focused on improving quality of life and relieving suffering, hoping to bring real value to the healthcare community along every step of the treatment pathway. We push ourselves to address the most complex and difficult issues facing people’s health to deliver better outcomes. This purpose driven approach ensures we deliver real impact, in a sustainable way, for patients and society.
Ipsen works across a diverse oncology portfolio in the U.K. and Ireland, which includes prostate cancer, neuroendocrine tumours, renal cell carcinoma, hepatocellular carcinoma and thyroid cancer.
ALLSC-UK-001850 | January 2025
ITM
ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global
network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com
SERB Pharmaceuticals
SERB Pharmaceuticals represents the combination of SERB, BTG Specialty Pharmaceuticals and Veriton Pharma Ltd to form a new, growing specialty pharmaceutical company focused on critical care and rare diseases.
We make treating complex and life-threatening conditions possible; supporting clinicians, healthcare systems and
governments while offering hope to patients and their families.
As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.
Improving patients’ quality of life and offering hope is what motivates and inspires us.
For future UKI NETS conferences
This is the leading NET conference in UK and Ireland and we have sponsorship packages available to offer you to make the most of your conference experience.
If you are interested in any of our sponsorship and exhibition opportunities for 2025, please email [email protected]
Patient Support Groups
UKI NETS would like to extend its thanks to both AMEND and NCUK for their continued support of the Annual Conference.